Literature DB >> 27217382

Nivolumab Doubles Survival for Patients with HNSCC.

.   

Abstract

In patients with head and neck squamous cell carcinoma refractory to platinum-based chemotherapy, those treated with nivolumab had a 30% reduction in the risk of death compared with those assigned to receive one of three single-agent chemotherapies, according to a recent phase III trial. In addition, 1-year survival among nivolumab recipients was double that of those who received a chemotherapeutic, the current standard of care. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27217382     DOI： 10.1158/2159-8290.CD-NB2016-049

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  8 in total

Review 1.  Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition.

Authors:  Arlene Siefker-Radtke; Brendan Curti
Journal:  Nat Rev Urol       Date:  2017-12-05       Impact factor: 14.432

2.  Urgent Need to Define Pretreatment Predictors of Immune Check Point Inhibitors Related Endocrinopathies: A Case Report and Review of Literature.

Authors:  Vishal Sehgal; Richard Childress
Journal:  J Transl Int Med       Date:  2017-12-29

Review 3.  Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC.

Authors:  J E Mann; R Hoesli; N L Michmerhuizen; S N Devenport; M L Ludwig; T R Vandenberg; C Matovina; N Jawad; M Mierzwa; A G Shuman; M E Spector; J C Brenner
Journal:  J Cancer       Date:  2017-02-09       Impact factor: 4.207

Review 4.  Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma.

Authors:  Paul Nghiem; Howard L Kaufman; Murtuza Bharmal; Lisa Mahnke; Hemant Phatak; Jürgen C Becker
Journal:  Future Oncol       Date:  2017-03-28       Impact factor: 3.404

5.  PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model.

Authors:  Yuan Li; Yang Du; Ting Sun; Huadan Xue; Zhengyu Jin; Jie Tian
Journal:  BMC Cancer       Date:  2018-06-19       Impact factor: 4.430

Review 6.  Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.

Authors:  Xiangfeng Shen; Lihong Zhang; Jicheng Li; Yulin Li; Yishu Wang; Zhi-Xiang Xu
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

7.  Increased PD-L1 expression in radioresistant HNSCC cell lines after irradiation affects cell proliferation due to inactivation of GSK-3beta.

Authors:  Daniela Schulz; Irene Stancev; Antonio Sorrentino; Ayse-Nur Menevse; Philipp Beckhove; Gero Brockhoff; Matthias Günther Hautmann; Torsten Erich Reichert; Richard Josef Bauer; Tobias Ettl
Journal:  Oncotarget       Date:  2019-01-15

8.  PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.

Authors:  Tim Müller; Martin Braun; Friedrich Bootz; Peter Brossart; Dimo Dietrich; Seher Aktekin; Simon Höft; Glen Kristiansen; Friederike Göke; Andreas Schröck; Johannes Brägelmann; Stefanie A E Held
Journal:  Oncotarget       Date:  2017-05-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.